BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
24h
Aktuell
Min
119.7
Max
122.55
Einkommen | -142M 667M |
---|---|
Verkäufe | 152M 5.4B |
KGV Branchendurchschnitt | 26.27 57.333 |
EPS | 2.2 |
Dividendenrendite | 1.34 |
Gewinnspanne | 12.311 |
EBITDA | 85M 1.6B |
Empfehlungen | Buy |
---|---|
12-Monats-Prognose | +38.83% upside |
Dividendenrendite Branchendurchschnitt | 1.34% 2.63% |
---|---|
Nächstes Ergebnis | 15. Mai 2025 |
Marktkapitalisierung | 33B 98B |
---|---|
Vorheriger Eröffnungskurs | 119.98 |
Vorheriger Schlusskurs | 121.4 |
By Trading Central
Vertrauen
Very Strong Bullish Evidence
117.55 / 120.4 Unterstützung & Widerstand
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
6. März 2025, 06:27 UTC
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
DJ
Lesen
11. Feb. 2025, 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
Lesen
10. Feb. 2025, 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
Lesen
24. Apr. 2025, 22:51 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update
DJ
Lesen
24. Apr. 2025, 20:54 UTC
Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into
DJ
Lesen
24. Apr. 2025, 20:50 UTC
Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share
DJ
Lesen
24. Apr. 2025, 19:05 UTC
Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ
DJ
Lesen
24. Apr. 2025, 19:05 UTC
Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ
DJ
Lesen
24. Apr. 2025, 19:05 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ
DJ
Lesen
24. Apr. 2025, 19:05 UTC
Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ
DJ
Lesen
6. März 2025, 11:18 UTC
Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk
DJ
Lesen
6. März 2025, 11:14 UTC
Merck KGaA's Outlook Signals Greater Transparency -- Market Talk
DJ
Lesen
6. März 2025, 08:20 UTC
Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA 2024 Adj EPS EUR8.63
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA 2024 EBIT EUR3.645B
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA 2024 After-Tax Profit EUR2.79B
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA 2024 EBITDA EUR5.78B
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA 2024 Sales EUR21.16B
DJ
Lesen
6. März 2025, 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20
DJ
Lesen
6. März 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Sales at EUR21.14B
DJ
Lesen
6. März 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B
DJ
Lesen
11. Feb. 2025, 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
Lesen
11. Feb. 2025, 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
Lesen
11. Feb. 2025, 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
Lesen
6. Jan. 2025, 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
Lesen
6. Jan. 2025, 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
Lesen
6. Jan. 2025, 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
Lesen
Kursveränderung
By TipRanks
12-Monats-Prognose
Durchschnitt 166.25 EUR 38.83%
Hoch 190 EUR
Tief 107 EUR
Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Merck KGaA – Dist angeboten haben.
By TipRanks
Buy
9 ratings
6
Buy
2
Halten
1
Sell
Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Merck KGaA – Dist abgegeben haben.
By Trading Central
Kurzfristig
Very Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Mittelfristig
Bearish Evidence
All events are bearish.
Langfristig
Bearish Evidence
All events are bearish.
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$